leadf
logo-loader
viewImugene Limited
(
ASX:IMUOTC:IUGNF
)

Imugene's Leslie Chong says Roth Capital Partners' report is 'great accomplishment'

Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong caught up with Proactive's Andrew Scott following the news California-based investment bank Roth Capital Partners has initiated coverage with a Buy rating and a 12-month price target of 13 cents. She says it's a great accomplishment for them to be told they're a buy and that's only on three of their compounds.

Quick facts: Imugene Limited

Follow
ASX:IMU

Price: 0.505 AUD

Market Cap: $2.73 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Imugene's Leslie Chong outlines key strategic partnership with Celularity

Imugene Ltd's Leslie Chong speaks to Proactive's Andrew Scott soon after announcing they've entered into a research collaboration with Celularity Inc to develop a novel oncolytic virus allogeneic CAR T-Cell immunotherapy combination for the treatment of solid tumors. As part of the partnership...

on 9/8/21

2 min read